IL-17A Regulates Autophagy and Promotes Osteoclast Differentiation Through the ERK/mTOR/Beclin1 Pathway

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2023 Feb 16

PMID 36795736

Authors

Hao Tang

Shida Zhu

Kai Chen

Shujie Yuan

Junzu Hu

Hongkai Wang

Affiliations

Soon will be listed here.

Abstract

Bone is a frequent target of tumor metastasis, with high incidence rate and poor prognosis. Osteoclasts play a key role in the process of tumor bone metastasis. Interleukin-17A (IL-17A) is an inflammatory cytokine, highly expressed in a variety of tumor cells, that can alter the autophagic activity of other cells, thereby causing corresponding lesions. Previous studies have shown that low concentration IL-17A can promote osteoclastogenesis. The aim of this study was to clarify the mechanism of low concentration IL-17A promoting osteoclastogenesis by regulating autophagic activity. The results of our study showed that IL-17A could promote the differentiation of osteoclast precursors (OCPs) into osteoclasts in the presence of RANKL, and increase the mRNA levels of osteoclast-specific genes. Moreover, IL-17A increased the expression of Beclin1 by inhibiting the phosphorylation of ERK and mTOR, leading to enhanced autophagy of OCPs, accompanied by decreased OCP apoptosis. Furthermore, knockdown of Beclin1 and suppression of autophagy by 3-methyladenine (3-MA) significantly attenuated the enhanced osteoclastogenesis induced by IL-17A. In summary, these results indicate that low concentration IL-17A enhances the autophagic activity of OCPs through the ERK/mTOR/Beclin1 pathway during osteoclastogenesis, and further promotes osteoclast differentiation, suggesting that IL-17A may serve as a potential therapeutic target for cancer-related bone resorption in cancer patients.

Citing Articles

Beclin 1 of megakaryocytic lineage cells is locally dispensable for platelet hemostasis but functions distally in bone homeostasis.

Li L, Zhao C, Zhang R, Wei W, Liu B, Dong J Bone Res. 2025; 13(1):32.

PMID: 40032858 PMC: 11876339. DOI: 10.1038/s41413-025-00410-7.

Identification and functional analysis of genes mediating osteoclast-driven progression of osteoporosis.

Xu Q, Feng G, Zhang Z, Yan J, Tang Z, Wang R Sci Prog. 2024; 107(4):368504241300723.

PMID: 39587887 PMC: 11590132. DOI: 10.1177/00368504241300723.

Lysosomal biogenesis and function in osteoclasts: a comprehensive review.

Jiang J, Ren R, Fang W, Miao J, Wen Z, Wang X Front Cell Dev Biol. 2024; 12:1431566.

PMID: 39170917 PMC: 11335558. DOI: 10.3389/fcell.2024.1431566.

Balancing the Scales: The Dual Role of Interleukins in Bone Metastatic Microenvironments.

Dawalibi A, Alosaimi A, Mohammad K Int J Mol Sci. 2024; 25(15).

PMID: 39125732 PMC: 11311339. DOI: 10.3390/ijms25158163.

IL-17A deficiency inhibits lung cancer-induced osteoclastogenesis by promoting apoptosis of osteoclast precursor cells.

Wang H, Tang H, Yuan S, Liang C, Li Y, Zhu S PLoS One. 2024; 19(2):e0299028.

PMID: 38394046 PMC: 10889641. DOI: 10.1371/journal.pone.0299028.

References

Wang H, Shen W, Hu X, Zhang Y, Zhuo Y, Li T . Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways. Breast Cancer Res Treat. 2015; 149(3):705-14. DOI: 10.1007/s10549-015-3290-x. View

Adamopoulos I, Chao C, Geissler R, LaFace D, Blumenschein W, Iwakura Y . Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res Ther. 2010; 12(1):R29. PMC: 2875663. DOI: 10.1186/ar2936. View

DArcy M . A review of biologically active flavonoids as inducers of autophagy and apoptosis in neoplastic cells and as cytoprotective agents in non-neoplastic cells. Cell Biol Int. 2022; 46(8):1179-1195. DOI: 10.1002/cbin.11813. View

Das S, Shukla N, Singh S, Kushwaha S, Shrivastava R . Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. 2021; 26(9-10):512-533. DOI: 10.1007/s10495-021-01687-9. View

Song L, Tan J, Wang Z, Ding P, Tang Q, Xia M . Interleukin‑17A facilitates osteoclast differentiation and bone resorption via activation of autophagy in mouse bone marrow macrophages. Mol Med Rep. 2019; 19(6):4743-4752. PMC: 6522800. DOI: 10.3892/mmr.2019.10155. View

Zhao E, Feng L, Bai L, Cui H . NUCKS promotes cell proliferation and suppresses autophagy through the mTOR-Beclin1 pathway in gastric cancer. J Exp Clin Cancer Res. 2020; 39(1):194. PMC: 7504682. DOI: 10.1186/s13046-020-01696-7. View

Orosz L, Papanicolaou E, Seprenyi G, Megyeri K . IL-17A and IL-17F induce autophagy in RAW 264.7 macrophages. Biomed Pharmacother. 2016; 77:129-34. DOI: 10.1016/j.biopha.2015.12.020. View

Del Conte A, De Carlo E, Bertoli E, Stanzione B, Revelant A, Bertola M . Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications. Int J Mol Sci. 2022; 23(12). PMC: 9224636. DOI: 10.3390/ijms23126832. View

Wang R, Yang L, Zhang C, Wang R, Zhang Z, He Q . Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer. Oncoimmunology. 2018; 7(11):e1461303. PMC: 6205058. DOI: 10.1080/2162402X.2018.1461303. View

10.

Weilbaecher K, Guise T, McCauley L . Cancer to bone: a fatal attraction. Nat Rev Cancer. 2011; 11(6):411-25. PMC: 3666847. DOI: 10.1038/nrc3055. View

11.

Montaseri A, Giampietri C, Rossi M, Riccioli A, Del Fattore A, Filippini A . The Role of Autophagy in Osteoclast Differentiation and Bone Resorption Function. Biomolecules. 2020; 10(10). PMC: 7601508. DOI: 10.3390/biom10101398. View

12.

Song X, Wei C, Li X . The potential role and status of IL-17 family cytokines in breast cancer. Int Immunopharmacol. 2021; 95:107544. DOI: 10.1016/j.intimp.2021.107544. View

13.

Ell B, Kang Y . SnapShot: Bone Metastasis. Cell. 2012; 151(3):690-690.e1. DOI: 10.1016/j.cell.2012.10.005. View

14.

Kitami S, Tanaka H, Kawato T, Tanabe N, Katono-Tani T, Zhang F . IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells. Biochimie. 2010; 92(4):398-404. DOI: 10.1016/j.biochi.2009.12.011. View

15.

Lu H, Hu H, Li S . Diagnostic value of beclin-1 and mTOR in ovarian cancer. Int J Clin Exp Pathol. 2021; 14(2):238-246. PMC: 7868785. View

16.

Minkin C . Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int. 1982; 34(3):285-90. DOI: 10.1007/BF02411252. View

17.

Maurizi A, Rucci N . The Osteoclast in Bone Metastasis: Player and Target. Cancers (Basel). 2018; 10(7). PMC: 6071064. DOI: 10.3390/cancers10070218. View

18.

Rinaldi S, Santoni M, Leoni G, Fiordoliva I, Marcantognini G, Meletani T . The prognostic and predictive role of hyponatremia in patients with advanced non-small cell lung cancer (NSCLC) with bone metastases. Support Care Cancer. 2018; 27(4):1255-1261. DOI: 10.1007/s00520-018-4489-2. View

19.

Lin N, Stefanica A, Distler J . Autophagy: a key pathway of TNF-induced inflammatory bone loss. Autophagy. 2013; 9(8):1253-5. PMC: 3748199. DOI: 10.4161/auto.25467. View

20.

Kim H, Yoon H, Lee D, Jin X, Che X, Choi J . The estrogen-related receptor γ modulator, GSK5182, inhibits osteoclast differentiation and accelerates osteoclast apoptosis. BMB Rep. 2021; 54(5):266-271. PMC: 8167243. View